About Arkansas Epilepsy Program

Dr. Victor Biton is the owner and director of Arkansas Epilepsy Program. In 1990, Dr. Biton completed his specialty training in epilepsy in Minneapolis, Minnesota. Shortly thereafter, Dr. Biton and his family decided to relocate to Little Rock, Arkansas where Dr. Biton served as the Director of the Epilepsy Program at UAMS and the VA hospital. In 1994 Dr. Biton started his own private practice, Arkansas Epilepsy Program, to serve as a comprehensive epilepsy program serving Arkansas and the surrounding areas.

AEP strives to hire and retain the most experienced and specialized staff in the area. Our staff includes EEG technicians with many years of experience, trained lab technicians, an experienced specialty nurse, and support operations contracted through a major hospital system in the area (www.practice-plus.com).

Dr. Biton is considered one of the foremost experts in his field; below are some of his many publications from recent years.

Featured Publications

Articles / Chapters

Biton V. Lacosamide for the Treatment of Partial-Onset Seizures. Expert Rev. Neurother 2012; 12(6): 645–655.

Sandercock D, Cramer M, Biton V, Cowles VE. A Gastroretentive Gabapentin Formulation for the Treatment of Painful Diabetic Peripheral Neuropathy: Efficacy and Tolerability in a Double- Blind, Randomized, Controlled Clinical Trial. Diabetes Res Clin Pract 2012; Apr 10. [Epub ahead of print]

Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, and Narurkar M. A Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Rufinamide as Adjunctive Therapy for Refractory Partial-Onset Seizures. Epilepsia 2011; 52(2): 234– 242. [Published Online: October 1, 2010. (DOI: 10.1111/j.1528-1167.2009.02729.x)].

Chung S, Sperling M, Biton V, Krauss G, Hebert D, Rudd G, and Doty P. Lacosamide as Adjunctive Therapy for Partial-Onset Seizures: A Randomized Controlled Trial. Epilepsia 2010; 51(6): 958–967 (doi: 10.1111/j.1528-1167.2009.02496.x).

Biton V. The Treatment of Epilepsy (Shorvon S, Perucca E, Engel J, eds.). 3rd ed., Blackwell Publishing, 2009 (chapter 51: Rufinamide; 647-657).

Sandercock D, Cramer M, Wu J, Chiang Y, Biton V, Heritier M. Gabapentin Extended Release for the Treatment of Painful Diabetic Peripheral Neuropathy: Efficacy and Tolerability in a Double-blind, Randomized, Controlled Clinical Trial. Diabetes Care (online) Feb 2009; 32 (2).

Biton V. Lamotrigine for Pediatric Patients with Epilepsy. Pediatric Health 2008; 2 (2): 125-134.

Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous Lacosamide as Replacement for Oral Lacosamide in Patients with Partial-Onset Seizures. Epilepsia 2008; 49(3): 418-424.

Biton, V. Lacosamide for the Treatment of Diabetic Neuropathic Pain. Expert Review of Neurotherapeutics 2008; 8(11): 1649-1660.

Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in Painful Diabetic Neuropathy: A Phase 2 Double-Blind Placebo-Controlled Study. Clinical Journal of Pain 2007; 23(2): 150-158.

Biton, V. Clinical Pharmacology and Mechanism of Action of Zonisamide. Clinical Neuropharmacology 2007; 30 (4): 230-240.

Biton V. Pharmacokinetics, Toxicology, and Safety of Lamotrigine in Epilepsy. Expert Opin Drug Metab Toxicol 2006; 2(6): 1009-1018.

Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojärvi J. Cognitive Effects of Lamotrigine Compared with Topiramate in Patients with Epilepsy. Neurology 2006; 67(3): 400-406.

Biton V. Weight Change and Antiepileptic Drugs: Health Issues and Criteria for Appropriate Selection of an Antiepileptic Agent. Neurologist 2006; 12(3): 163-167.

Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer, JA. Double-Blind, Placebo-Controlled Study of Lamotrigine in Primary Generalized Tonic-Clonic Seizures. Neurology 2005; 65: 1737-1743.

Biton V, Bourgeois BFD. Topiramate in Patients with Juvenile Myoclonic Epilepsy. Archives of Neurology 2005; 62(11): 1705-1708.

Sale ME, Natarajan S, Biton V, Vuong A, Hammer AE, Messenheimer JA, Blum D. A Dosing Algorithm for Converting from Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy. Epilepsy and Behavior 2005; 6: 63-70.

Biton V. Zonisamide: New Antiepileptic Agent with Multiple Mechanisms of Action. Expert Rev Neurotherapeutics 2004; 4(6): 935-943.

Biton V. Rufinamide. In: Shorvon S, Perucca E, Fish D, Dodson E, eds. The Treatment of Epilepsy, 4th ed. Oxford: Blackwell Publishing, 2004; 43: 500-506.

Biton V. Antiepileptic Drugs and Weight Gain. SYCP Epilepsy 2003; 10(2): 3-6.

Sommerville KW, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs. Clin Drug Invest 2003; 23(10): 661- 670.

Leppik IE, Biton V, Sander JW, Wieser HG. Levetiracetam and Partial Seizure Subtypes: Pooled Data From Three Randomized, Placebo-Controlled Trials. Epilepsia 2003; 44 Suppl.12: 1585- 1587.

Biton V. Effect of Antipeileptic Drugs on Bodyweight: Overview and Clinical Implications for the Treatment of Epilepsy. CNS Drugs 2003; 17(11): 781-791.

Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus Valproate Monotherapy Associated Weight Change in Adolescents with Epilepsy: Results from a Post Hoc Analysis of a Randomized, Double-Blind Clinical Trial. J Child Neurol 2003; 18 (2): 133-139.

Gilliam FG, Veloso F, Bomhof MAM, Gazda SK, Biton V, Ter Bruggen JP, Neto W, Bailey C, Pledger G, Wu S-C, Topiramate EPMN 104 Study Group. A Dose-Comparison Trial of Topiramate as Monotherapy in Recently Diagnosed Partial Epilepsy. Neurology 2003; 60: 196-202.

Biton V. Levetiracetam: Adverse Effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002: 442-447.

Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight Change Associated with Valproate and Lamotrigine Monotherapy in Patients with Epilepsy. Neurology 2001; 56: 172- 177.

Biton V, Edwards K, Montouris G, Sackellares J, Harden C, Kamin M. A Comparison of Titration Rates on Tolerability and Efficacy of Topiramate Initiated as Adjunctive Therapy. Ann Pharmacother 2001; 35: 173-179.

Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Guiliani M, Stevens JC, Barbano R, Dyck PJ, rhNGF Clinical Investigator Group. Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients with Diabetic Polyneuroapthy. JAMA 2000; 284: 2215-2221.

Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for Partial Seizures: Results of a Double-Blind, Randomized Clinical Trial. Neurology 2000; 55: 236- 242. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. A Randomized, Placebo- Controlled Study of Topiramate in Primary Generalized Tonic-Clonic Seizures. Neurology 1999; 52: 1330-1337.

Honeycutt J, Boop FA, Biton V, Sharp GB, Griebel ML, Galbraith R. Results of Temporal Lobectomy for the Treatment of Partial Complex Epilepsy. J Ark Med Society 1994; 91(7): 329-333.

Biton V, Gates J, DePadua E. Prolonged Postictal Encephalopathy. Neurology 1990; 40: 963-966.

Biton V, Gates J, Ritter F, Loewenson R. Adjunctive Therapy for Intractable Epilepsy with Ethotoin. Epilepsia 1990 Jul-Aug; 31(4): 433-437.

Melamed E, Biton V, Zelig O. Episodic Unresponsiveness to Single Doses of L-Dopa in Parkinsonian Fluctuators. Neurology 1986; 36: 100-103.

Melamed E, Biton V, Zelig O. Delayed Onset of Responses to Single Doses of L-Dopa in Parkinsonian Fluctuators in Long Term L-Dopa Therapy. Clin Neuropharmacol 1986; 9(2): 182-188.

Gottlieb D, Fields S, Biton V, Gomori M, Kidron D, Melamed E. Clinical Roentgenological Study of Degenerative Spinocerebellar Diseases. Harefuah (Hebrew) 1986; 111: 165-167.

Biton V, Gomori JM, Gottlieb D, Melamed E. Superior Sagittal Sinus thrombosis: Clinical Picture and Computed Tomographic Findings. Harefuah (Hebrew) 1985; 108: 3-5.

Mathetias O, Soomer H, Biton V. Central Auditory Tests in Multiple Sclerosis. Acta Otolaryngol 1985; 99: 369-376.

Biton V, Melamed E. Coexistence of Severe Parkinsonism and Tardive Dyskinesia as Side Effects of Neuroleptic Therapy. J Clin Psychiatry 1984; 45: 28-30.

ABSTRACTS

Krauss G, Yang J, Biton V, Klapper J, Bar M, Rektor I. Determination of Maximum Tolerated Dose (MTD), Safety, Efficacy, and Pharmacokinetics (PK) of Perampanel, a Selective AMPA Receptor Antagonist, as Adjunctive Therapy in Subjects with Refractory Partial Seizures. (Abstract presented at the 62nd Annual Meeting of the American Epilepsy Society 2008) Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. Evaluation of the Effect of Oral Lacosamide on Concomitant AED Plasma Concentrations in Patients with Partial Seizures. Epilepsia 2005; 46 Suppl.8: 170.

Lesser RP, Biton V, Sackellares JC, Van Ness PC, Perdomo C, Arroyo S. Efficacy and Safety of Rufinamide Monotherapy for the Treatment of Patients with Refractory Partial Seizures. Epilepsia 2005; 46 Suppl.8: 177-178.

Rosenfeld W, Biton V, Mameniskiene R, Vaiciene N, Whitesides J, Schiltmeyer B, Sommerville K. Pharmacokinetics and Safety of Intravenous Lacosamide Administered as Replacement for Adjunctive Oral Lacosamide in Patients with Partial-Onset Seizures. Epilepsia 2005; 46 Suppl.8: 184.

Sachdeo R, Porter R, Biton V, Rosenfeld W, Alves W, Nohria V. Dose Finding Study of Retigabine (A Novel AED) in Patients with Epilepsy. Epilepsia 2005; 46 Suppl.8: 185.

Biton V, Sachdeo R, Rosenfeld W, Schachter S, Perdomo C, Arroyo S. Efficacy and Safety of Adjunctive Rufinamide in Patients with Inadequately Controlled Primary Generalized Tonic-Clonic Seizures. Epilepsia 2005; 46 Suppl.8: 206.

Biton V, Vuong A, Kerls S, Hammer A, Messenheimer J. Onset of Efficacy with Lamotrigine in Primary Generalized Tonic-Clonic Seizures (PGTCS): A Randomized, Placebo-Controlled Study. Epilepsia 2005; 46 Suppl.8: 206.

Todorov A, Biton V, Krauss GL, Perdomo C, Arroyo S. Efficacy and Safety of High- Versus Low-Dose Rufinamide Monotherapy in Patients with Inadequately Controlled Partial Seizures. Epilepsia 2005; 46 Suppl.8: 218-219.

Biton V, Rosenfeld W, Mameniskiene R, Vaiciene N, Whitesides J, Sommerville K. Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Subjects with Partial-Onset Seizures. Epilepsia 2005; 46 Suppl.6: 121.

Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd D, S.P. 667 Study Group. Efficacy and Safety of Adjunctive Oral Lacosamide for the Treatment of Partial Onset Seizures in Patients with Epilepsy. Epilepsia 2005; 46 Suppl.6: 57.

Biton V, Groenke DA, Hammer AE, Kustra RP, Messenheimer JA, Winter P. Evaluation and Comparison of Seizure Control During Escalation of Lamotrigine, Valproic Acid, Carbamazepine and Phenytoin as Initial Monotherapy in Patients with Epilepsy. Eur J Neurol 2003; 10(1): 141.

Biton V, Whitesides J, Doty P, Sommerville K. Safety and Efficacy of SPM 927 during the Initial Phase of an Extension Trial in Subjects with Partial Seizures. Epilepsia 2003; 44 Suppl.9: 259.

Biton V, Bebin ME. Multicenter, Open-Label Assessment of the Efficacy and Safety of Zonisamide as Adjunctive Therapy for Primary Generalized Epilepsy. Epilepsia 2002; 43 Suppl.7: 2.180.

Biton V, Blum D, Groenke D, Hammer A, Messenheimer J. Evaluation and Comparison of Seizure Control During Escalation of Lamotrigine, Valproic Acid, Carbamazepine and Phenytoin as Initial Monotherapy in Patients with Epilepsy. Epilepsia 2002; 43 Suppl.7: 2.183

Biton V. Weight Change Associated with Valproate And Lamotrigine Monotherapy In Patients with Epilepsy. [Letter] Neurology 2001; 57(3): 565-566.

Montouris G, Biton V, Rosenfeld W, YTC/YTCE Study Group. Nonfocal Generalized Tonic-Clonic Seizures: Response During Long-Term Treatment. Epilepsia 2000; 41 Suppl.1: S77-S81.

Mirza W, Biton V, Barrett P, Vuong A, Hammer A. Weight Gain Associated with Valproate Monotherapy in Patients with Epilepsy: An Interim Analysis of a Randomized, Double- Blinded Comparative Clinical Trial with Lamotrigine. Epilepsia 1999; 40 Suppl.2: 282.

Montouris G, Mirza WU, Biton V, Vuong A, Barrett P, Hammer A. Effects of Lamictal and Depakot Monotherapy on Body Weight in Patients with Epilepsy: Interim Analysis of a Randomized, Double-Blind Clinical Trial. Neurology 1999; 52(6) Suppl.2: A523-A524.

Abou-Khalil BW, Vazquez BR, Beydoun A, Elger CE, Biton V, Krauss GL, Smith TM, Greiner MJ, Knapp LE, Garofalo EA. Pregabalin In-Patient Monotherapy Trial: A Double-Blind, Low- Dose Active-Controlled, Multicenter Study in Patients with Refractory Partial Epilepsy. Neurology 1999; 52(6) Suppl.2: A390.

Biton V, Vasquez B, Sachdeo R, Lenz G, Deaton R, Sommerville K. Adjunctive Tiagabine Compared with Phenytoin and Carbamazepine in the Multicenter, Double-Blind Trial of Complex Partial Seizures. Epilepsia 1998; 39 Suppl.6: 125.

Vazquez B, Abou-Khalil B, Biton V, Smith T, Greiner M, Knapp L, Garofalo E. Pregabalin Monotherapy in Hospitalized Patients: A Study Design for Early Demonstration of Anticonvulsant Efficacy. Epilepsia 1998; 39 Suppl.6: 67.

Biton V, Chadwick D, Montouris GD, Shu-Chen W. Topiramate as Long-Term Therapy in Patients with Generalized Tonic-Clonic Seizures without Focal Onset. Neurology 1998; 50(4) Suppl.4: A311-A312.

Brodie MJ, Biton V, Montouris GD, Shu-Chen W. Topiramate Therapy in Patients with Generalized Tonic-Clonic Seizures without Focal Onset: Long-Term Outcome. Epilepsia 1998; 39 Suppl.2: 2.

Biton V, Montouris GD, Riviello JD, Reife R, & YTC Study Group. Efficacy And Safety Of Topiramate In Generalized Tonic-Clonic Seizures Of Nonfocal Origin. Epilepsia 1997; 38 Suppl.8: 206-207.

Biton V, Montouris GD, Riviello JD, Reife R, & Topiramate YTC Study Group. Topiramate as Add- On Therapy in Generalized Seizures of Nonfocal Origin. Ann Neurol 1997; 42(3): 502-503.

Sachdeo RC, Biton V, Abou-Khalil B. Seizure-Free Patients in Topiramate Clinical Trials. Epilepsia 1997; 38 Suppl.7: 13.

Boop FA, Biton V, Souheaver GT, Yasargil MG. Post-operative Verbal memory Performance in Patients Following Dominant Temporal Lobectomy versus Selective Amygdalohippocampectomy. Epilepsia 1997; 38 Suppl.3: 246.

Montouris GD, Biton V, & YTC Study Team. Long-term Topiramate Therapy in Generalized Seizures of Non-focal Origin. Epilepsia 1997; 38 Suppl.3: 82.

Biton V, Montouris GD, & YTC Study Team. Topiramate Double-Blind Trial in Patients with Generalised Tonic-Clonic Seizures Non-focal Origin. Epilepsia 1997; 38 Suppl.3: 59.

Biton V. Preliminary Open-Label Experience with Topiramate in Primary Generalized Seizures. Epilepsia 997; 38 Suppl.1: S42-S44.

Biton V, Boellner S, Mercante D, Phillips H, Alto G, Sommerville K. Monotherapy with Tiagabine in an Open-Label Study of Partial Seizures. Epilepsia 1996; 37 Suppl.4: 40.

Biton V, Alto G, Pixton G, Sommerville K. Tiagabine Monotherapy in Adults and Children in a Long- Term Study. Epilepsia 1996; 37 Suppl.5: 167.

Biton V, Reife R, Kamin M, Bobrosky K. Topiramate as Add-on Therapy for Patients with Primary Generalized Epilepsy. Neurology 1996; 46: A176.

Schachter S, Biton V, Boellner S, Edwards K, Cybulski K, Shu V, Hightower B, Sommerville K. Safety and Efficacy of Tiagabine HCl Monotherapy in the Treatment of Partial Seizures: High Dose versus Low Dose. Epilepsia 1995; Vol. 36, Suppl.3: S148.

Sachdeo RC, Biton V, Boellner SW, Schachter SC, Alto G, Kaply C, Philips HB, Kardatzke D, Pixton G, Sommerville KW. Long Term Safety of Tiagabine HCl. Epilepsia 1995; Vol. 36, Suppl.4: 55.

Schachter S, Biton V, Bergen D, Ahmann P, Rask CA, Smith S, Deaton R, Patterson R. Long-Term Safety of Tiagabine HCl. Epilepsia 1993; 34, Suppl.6: 67.

Biton V, Boop R. Ethotoin - A Last Resort Anti-Epileptic Drug. Epilepsia 1991; 32, Suppl.3: 61.

Biton V, Fiol M, Gates J. Do Ictal Events Originate from Areas of Inter-Ictal Activity? A Chronically Implanted Subdural Electrode Study. Epilepsia 1989 Oct; (30)5: 694.

Fiol M, Gates J, Biton V, Maxwell R. The Value of Subdural Electrode Array in the Surgical Treatment of Patients with Widespread Temporal Lobe Interictal Activity or Solitary Midposterior Temporal MRI Lesions. Epilepsia 1989; (30)5: 694.

Biton V, Fiol M, Gates J, Maxwell R. Inhibitory Sensory Locus Defined by Direct Cortical Stimulation. J Clin Neurophysiol 1988; (5)4: 338-339.

Biton V, Abramsky O. Newer Study Fails to Support Environmental Factors in Etiology of Multiple Sclerosis. Neurology 1986; 36: 184.

Melamed E, Biton V, Zelig O. Less Recognized Side Effects of Chronic Dopatherapy that may be caused by Faculty Absorption of L-Dopa: studies in Parkinsonian Fluctuators. Neurology 1985; 232 Suppl: 192.

Melamed E, Biton V. Delayed Onset of Responses to Individual Doses of L-Dopa in Parkinsonian Fluctuators: An Additional Side Effect of Long Term L-Dopa Therapy. Neurology 1984; 34 Suppl.2: 270.

Contact Us

501-227-5061 Phone
501-227-5234 Fax
888-527-5061 Toll Free

#2 Lile Court Suite 100
Little Rock, Arkansas 72205
srhichens@practice-plus.com

Little Rock Office Location